Nuvectis Pharma Reports Q2 2026 Financial Results and Corporate Update

What Happened

• Nuvectis Pharma, Inc. announced on August 4, 2026 that it issued a press release providing a corporate update and reporting its financial results for the quarter ended June 30, 2026. The company furnished that press release as Exhibit 99.1 to the Form 8-K. The information in the filing is furnished (not “filed”) under SEC rules.

Key Details

• Announcement date: August 4, 2026.
• Reporting period: Second quarter ended June 30, 2026.
• Exhibit furnished: Press release dated August 4, 2026 (Exhibit 99.1).
• Technical exhibit: Cover Page Interactive Data File in iXBRL format (Exhibit 104).
• The Form 8-K classification: Item 2.02 (Results of operations and financial condition); information is furnished and not subject to Section 18 liability.

Why It Matters

• This 8-K signals that Nuvectis has publicly released its Q2 2026 operating and financial results and provided corporate commentary—information investors typically use to assess near-term performance.
• Because the press release is furnished as an exhibit, investors should read Exhibit 99.1 for the specific financial figures, management commentary, and any guidance or operational updates.
• The “furnished, not filed” designation means the press release is not subject to certain liability provisions under the Exchange Act; investors should verify details in the press release and related filings for investment decisions.